Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: a pilot clinical trial.

摘要: The elderly population is susceptible to haematological malignancies, and these patients are intolerant cytotoxic drugs. Therefore, the exploration of a safe reliable strategy exclusive chemotherapy critical in improving prognosis with malignancies. We evaluated safety efficacy autologous cytokine-induced killer (CIK) cells combined recombinant human interleukin 2 (rhIL-2) treatment malignancies patients. Peripheral blood mononuclear were isolated from 20 then augmented by priming interferon gamma, rhIL-2 CD3 monoclonal antibody. CIK (2-3 × 10(9)) transfused back patients, followed subcutaneous injection IL-2 (1 mU/day) for 10 consecutive days. regimen was repeated every 4 weeks. host cellular immune function, tumour-related biological parameters, imaging characteristics, disease condition, quality life survival time assessed. Fourteen received 8 cycles transfusion 6 cycles. No adverse effects observed. percentages CD3(+), CD3(+) CD8(+) CD56(+) significantly increased (p < 0.05), levels serum β2 microglobulin lactate dehydrogenase (LDH) markedly decreased 0.05) after cell transfusion. Cancer-related symptoms profoundly alleviated, as demonstrated improved 0.01). Complete remission observed 11 persistent partial 7 stable At end follow-up, mean months. Transfusion plus effective treating